Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.

In elderly HL patients, BV monotherapy showed a CR rate of 73% with no notable liver injury, suggesting that BV could be safe for patients with comorbidities [[3]]. Dear Editor, Severe liver injury in patients with Hodgkin lymphoma (HL) is uncommon, leading to a lack of experience in treating this entity. The use of BV in patients with liver impairment was further supported in a series of 5 previously untreated cHL patients with hepatocellular or cholestatic pattern of liver injury, where BV provided successful bridging to definitive chemotherapy with no serious adverse effects [[4]]. [Extracted from the article]